MYGN has been the topic of several other research reports. Zacks Investment Research lowered Myriad Genetics from a buy rating to a hold rating in a report on Monday, January 21st. Cowen upgraded Myriad Genetics from a market perform rating to an outperform rating in a report on Friday, January 4th. Needham & Company LLC began coverage on Myriad Genetics in a research report on Wednesday, January 2nd. They issued a strong-buy rating and a $36.00 price objective on the stock. Finally, Barclays cut their price objective on Myriad Genetics from $23.00 to $21.00 and set an underweight rating on the stock in a research report on Thursday, January 3rd. Three analysts have rated the stock with a sell rating, four have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of $40.37.
NASDAQ:MYGN opened at $31.75 on Wednesday. Myriad Genetics has a fifty-two week low of $26.05 and a fifty-two week high of $50.44. The firm has a market cap of $2.33 billion, a P/E ratio of 23.69, a P/E/G ratio of 1.42 and a beta of 0.58. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.68 and a current ratio of 2.97.
In other Myriad Genetics news, insider Ralph L. Mcdade sold 1,975 shares of the company’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $31.00, for a total value of $61,225.00. Following the transaction, the insider now owns 122,604 shares of the company’s stock, valued at approximately $3,800,724. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 5.80% of the company’s stock.
A number of institutional investors have recently made changes to their positions in MYGN. Oregon Public Employees Retirement Fund bought a new position in shares of Myriad Genetics during the 4th quarter worth $28,000. Financial Gravity Companies Inc. bought a new position in shares of Myriad Genetics during the 4th quarter worth $42,000. Investors Research Corp bought a new position in shares of Myriad Genetics during the 1st quarter worth $46,000. Financial Gravity Wealth Inc. bought a new position in shares of Myriad Genetics during the 1st quarter worth $56,000. Finally, Nisa Investment Advisors LLC grew its position in shares of Myriad Genetics by 625.0% during the 1st quarter. Nisa Investment Advisors LLC now owns 2,320 shares of the company’s stock worth $77,000 after buying an additional 2,000 shares in the last quarter. 99.22% of the stock is currently owned by institutional investors.
Myriad Genetics Company Profile
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Further Reading: Preferred Stock
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.